Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...

On June 9, 2025, clinicians, research trainees, and physician-scientists came together to present research and findings in the field of spine surgery at SpineFEST 2025. Hosted by the U of T Spine ...

Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials ...

A machine learning tool’s analysis of over 140,000 factors outperforms a fracture liaison service approach to fracture risk ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment ...

The various roles for oncology nurses in the conduct of clinical trials were described in a presentation at the 2025 ONS Bridge virtual meeting.

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...